Lucinda Y. Quan - Feb 4, 2022 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Executive Vice President, Chief Business Officer and General Counsel
Signature
/s/ Lucinda Y. Quan
Stock symbol
ALGS
Transactions as of
Feb 4, 2022
Transactions value $
$0
Form type
4
Date filed
2/8/2022, 03:07 PM
Next filing
Jul 11, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Award $0 +105K $0.00 105K Feb 4, 2022 Common Stock 105K $3.06 Direct F1
transaction ALGS Stock Option (Right to Buy) Award $0 +26.3K $0.00 26.3K Feb 4, 2022 Common Stock 26.3K $3.06 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
F2 100% of the shares subject to the Option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through such vesting date.

Remarks:

Executive Vice President, Chief Business Officer and General Counsel